Menu Back to Poster-Presentations-Details
T 11: Bridging the Gap: The Need for a Paradigm Shift in Clinical Trial Design to Ensure Continued Patient Access to Medicines
- Senior Director
- Parexel Access
Publically available NICE guidance documents and IQWiG press releases were screened for any oncology drug receiving negative appraisals by IQWiG or NICE from January 2012 until September 2015 and the key rationale was extracted.